References analysis of the Wikipedia article "Anthracycline" in the English version

doi.org

Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, Wang AH (March 1990). "Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin". Biochemistry. 29 (10): 2538–49. doi:10.1021/bi00462a016. PMID 2334681.

Fujiwara A, Hoshino T, Westley J (1985). "Anthracycline Antibiotics". Critical Reviews in Biotechnology. 3 (2): 133–157. doi:10.3109/07388558509150782.

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (February 2017). "Anthracycline Chemotherapy and Cardiotoxicity". Cardiovascular Drugs and Therapy. 31 (1): 63–75. doi:10.1007/s10557-016-6711-0. PMC 5346598. PMID 28185035.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (June 2004). "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity". Pharmacological Reviews. 56 (2): 185–229. doi:10.1124/pr.56.2.6. PMID 15169927. S2CID 13138853.

Peng X, Chen B, Lim CC, Sawyer DB (June 2005). "The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine". Molecular Interventions. 5 (3): 163–71. doi:10.1124/mi.5.3.6. PMID 15994456.

Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (May 2011). "Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy". Cancer. 117 (9): 1917–27. doi:10.1002/cncr.25691. PMC 3640637. PMID 21509769.

Dimarco A, Gaetani M, Orezzi P, Scarpinato BM, Silvestrini R, Soldati M, Dasdia T, Valentini L (February 1964). "'Daunomycin', a new antibiotic of the rhodomycin group". Nature. 201 (4920): 706–7. Bibcode:1964Natur.201..706D. doi:10.1038/201706a0. PMID 14142092. S2CID 4292271.

Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C (November 1969). "Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius". Biotechnology and Bioengineering. 11 (6): 1101–10. doi:10.1002/bit.260110607. PMID 5365804. S2CID 21897153.

Blum RH, Carter SK (February 1974). "Adriamycin. A new anticancer drug with significant clinical activity". Annals of Internal Medicine. 80 (2): 249–59. doi:10.7326/0003-4819-80-2-249. PMID 4590654.

Takemura G, Fujiwara H (March 2007). "Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management". Progress in Cardiovascular Diseases. 49 (5): 330–52. doi:10.1016/j.pcad.2006.10.002. PMID 17329180.

Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (March 2016). "Mitoxantrone, More than Just Another Topoisomerase II Poison". Medicinal Research Reviews. 36 (2): 248–99. doi:10.1002/med.21364. PMID 26286294. S2CID 8973790.

Marinello J, Delcuratolo M, Capranico G (November 2018). "Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives". International Journal of Molecular Sciences. 19 (11): 3480. doi:10.3390/ijms19113480. PMC 6275052. PMID 30404148.

Wahba HA, El-Hadaad HA (June 2015). "Current approaches in treatment of triple-negative breast cancer". Cancer Biology & Medicine. 12 (2): 106–16. doi:10.7497/j.issn.2095-3941.2015.0030 (inactive 1 November 2024). PMC 4493381. PMID 26175926.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)

Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA (February 2017). "Doxorubicin: nanotechnological overviews from bench to bedside". Drug Discovery Today. 22 (2): 270–281. doi:10.1016/j.drudis.2016.11.005. hdl:11336/47838. PMID 27890669.

Poon RT, Borys N (February 2009). "Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer". Expert Opinion on Pharmacotherapy. 10 (2): 333–43. doi:10.1517/14656560802677874. PMID 19236203. S2CID 73112213.

Mukai H, Kogawa T, Matsubara N, Naito Y, Sasaki M, Hosono A (June 2017). "A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors". Investigational New Drugs. 35 (3): 307–314. doi:10.1007/s10637-016-0422-z. PMID 28054329. S2CID 596267.

Nishiyama N, Matsumura Y, Kataoka K (July 2016). "Development of polymeric micelles for targeting intractable cancers". Cancer Science. 107 (7): 867–74. doi:10.1111/cas.12960. PMC 4946707. PMID 27116635.

Guo B, Tam A, Santi SA, Parissenti AM (September 2016). "Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells". BMC Cancer. 16 (1): 762. doi:10.1186/s12885-016-2790-3. PMC 5043608. PMID 27687594.

Gewirtz DA (April 1999). "A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin". Biochemical Pharmacology. 57 (7): 727–41. doi:10.1016/S0006-2952(98)00307-4. PMID 10075079.

Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F (August 2001). "Anthracyclines: selected new developments". Current Medicinal Chemistry. Anti-Cancer Agents. 1 (2): 113–30. doi:10.2174/1568011013354723. PMID 12678762.

Angsutararux P, Luanpitpong S, Issaragrisil S (2015). "Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress". Oxidative Medicine and Cellular Longevity. 2015: 795602. doi:10.1155/2015/795602. PMC 4602327. PMID 26491536.

Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V (January 2009). "Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron". Pharmacological Reports. 61 (1): 154–71. doi:10.1016/S1734-1140(09)70018-0. PMID 19307704. S2CID 4728513.

Cutts SM, Rephaeli A, Nudelman A, Ugarenko M, Phillips DR (2015). "Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent". Current Topics in Medicinal Chemistry. 15 (14): 1409–22. doi:10.2174/1568026615666150413154512. PMID 25866273.

Cutts SM, Nudelman A, Rephaeli A, Phillips DR (February 2005). "The power and potential of doxorubicin-DNA adducts". IUBMB Life. 57 (2): 73–81. doi:10.1080/15216540500079093. PMID 16036566. S2CID 6784020.

Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, et al. (May 2015). "Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also". Journal of Clinical Oncology. 33 (15): 1680–7. doi:10.1200/JCO.2013.54.7869. PMID 25897160.

Jing Liu; Sarah Lane (December 23, 2022). "Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice". Science Advances. 8 (51): eadc9245. Bibcode:2022SciA....8C9245L. doi:10.1126/sciadv.adc9245. PMC 9788780. PMID 36563141. (research conducted on patients affected by breast cancer).

Scully RE, Lipshultz SE (2007). "Anthracycline cardiotoxicity in long-term survivors of childhood cancer". Cardiovascular Toxicology. 7 (2): 122–8. doi:10.1007/s12012-007-0006-4. PMID 17652816. S2CID 834412.

Ewer MS, Ewer SM (September 2015). "Cardiotoxicity of anticancer treatments". Nature Reviews. Cardiology. 12 (9): 547–58. doi:10.1038/nrcardio.2015.65. PMID 25962976. S2CID 9317756.

Vejpongsa P, Yeh ET (January 2014). "Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity". Clinical Pharmacology and Therapeutics. 95 (1): 45–52. doi:10.1038/clpt.2013.201. PMID 24091715. S2CID 565837.

Gabizon A, Shmeeda H, Barenholz Y (2003). "Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies". Clinical Pharmacokinetics. 42 (5): 419–36. doi:10.2165/00003088-200342050-00002. PMID 12739982. S2CID 29494837.

Jordan K, Behlendorf T, Mueller F, Schmoll HJ (April 2009). "Anthracycline extravasation injuries: management with dexrazoxane". Therapeutics and Clinical Risk Management. 5 (2): 361–6. doi:10.2147/tcrm.s3694. PMC 2697522. PMID 19536310.

Chou H, Lin H, Liu JM (2015-07-13). "A tale of the two PEGylated liposomal doxorubicins". OncoTargets and Therapy. 8: 1719–20. doi:10.2147/OTT.S79089. PMC 4508070. PMID 26203262.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC (June 2011). "Cardioprotective interventions for cancer patients receiving anthracyclines". The Cochrane Database of Systematic Reviews. 2016 (6): CD003917. doi:10.1002/14651858.cd003917.pub4. PMC 6457676. PMID 21678342.

Araujo FI, Proença FP, Ferreira CG, Ventilari SC, Rosado de Castro PH, Moreira RD, Fonseca LM, Souza SA, Gutfilen B (August 2015). "Use of (99m)Tc-doxorubicin scintigraphy in females with breast cancer: a pilot study". The British Journal of Radiology. 88 (1052): 20150268. doi:10.1259/bjr.20150268. PMC 4651371. PMID 26111270.

Perez EA (March 2009). "Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer". Breast Cancer Research and Treatment. 114 (2): 195–201. doi:10.1007/s10549-008-0005-6. PMID 18443902. S2CID 7302079.

Arnason T, Harkness T (October 2015). "Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1". Cancers. 7 (4): 2063–82. doi:10.3390/cancers7040877. PMC 4695877. PMID 26501324.

Fan Y, Zhang Q (April 2013). "Development of liposomal formulations: From concept to clinical investigations". Asian Journal of Pharmaceutical Sciences. 8 (2): 81–87. doi:10.1016/j.ajps.2013.07.010.

Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015-12-01). "Advances and Challenges of Liposome Assisted Drug Delivery". Frontiers in Pharmacology. 6: 286. doi:10.3389/fphar.2015.00286. PMC 4664963. PMID 26648870.

Barenholz Y (June 2012). "Doxil®--the first FDA-approved nano-drug: lessons learned". Journal of Controlled Release. 160 (2): 117–34. doi:10.1016/j.jconrel.2012.03.020. PMID 22484195.

Soloman R, Gabizon AA (February 2008). "Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin". Clinical Lymphoma & Myeloma. 8 (1): 21–32. doi:10.3816/CLM.2008.n.001. PMID 18501085.

Haran G, Cohen R, Bar LK, Barenholz Y (September 1993). "Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1151 (2): 201–15. doi:10.1016/0005-2736(93)90105-9. PMID 8373796.

Maeda H, Nakamura H, Fang J (January 2013). "The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo". Advanced Drug Delivery Reviews. 65 (1): 71–9. doi:10.1016/j.addr.2012.10.002. PMID 23088862.

Batist G (2007). "Cardiac safety of liposomal anthracyclines". Cardiovascular Toxicology. 7 (2): 72–4. CiteSeerX 10.1.1.529.9071. doi:10.1007/s12012-007-0014-4. PMID 17652807. S2CID 2815965.

Batist G, Barton J, Chaikin P, Swenson C, Welles L (December 2002). "Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy". Expert Opinion on Pharmacotherapy. 3 (12): 1739–51. doi:10.1517/14656566.3.12.1739. PMID 12472371. S2CID 46242391.

Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S (August 2009). "Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet)". Breast. 18 (4): 218–24. doi:10.1016/j.breast.2009.05.004. PMID 19656681.

Swenson CE, Perkins WR, Roberts P, Janoff AS (June 2001). "Liposome technology and the development of Myocet™(liposomal doxorubicin citrate)". The Breast. 10: 1–7. doi:10.1016/S0960-9776(01)80001-1.

Bulbake U, Doppalapudi S, Kommineni N, Khan W (March 2017). "Liposomal Formulations in Clinical Use: An Updated Review". Pharmaceutics. 9 (2): 12. doi:10.3390/pharmaceutics9020012. PMC 5489929. PMID 28346375.

Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE (December 2004). "Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study". Cancer Chemotherapy and Pharmacology. 54 (6): 514–24. doi:10.1007/s00280-004-0825-y. PMID 15322827. S2CID 24630910.

Kivistö KT, Kroemer HK, Eichelbaum M (December 1995). "The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions". British Journal of Clinical Pharmacology. 40 (6): 523–30. doi:10.1111/j.1365-2125.1995.tb05796.x. PMC 1365206. PMID 8703657.

Tacar O, Sriamornsak P, Dass CR (February 2013). "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems". The Journal of Pharmacy and Pharmacology. 65 (2): 157–70. doi:10.1111/j.2042-7158.2012.01567.x. PMID 23278683. S2CID 34737360.

Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF (September 2007). "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane". Cancer Research. 67 (18): 8839–46. doi:10.1158/0008-5472.CAN-07-1649. PMID 17875725.

Ewer MS, Ewer SM (September 2010). "Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction". Journal of Clinical Oncology. 28 (25): 3901–4. doi:10.1200/JCO.2010.30.6274. PMID 20679626.

Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T (September 2008). "Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies". Annals of Oncology. 19 (9): 1530–9. doi:10.1093/annonc/mdn292. PMID 18480068.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (March 2001). "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2". The New England Journal of Medicine. 344 (11): 783–92. doi:10.1056/NEJM200103153441101. PMID 11248153.

Gianni L, Viganò L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G (May 1997). "Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer". Journal of Clinical Oncology. 15 (5): 1906–15. doi:10.1200/JCO.1997.15.5.1906. PMID 9164201.

nih.gov

pubmed.ncbi.nlm.nih.gov

Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670–86. PMID 1462166.

Dubost M, Ganter P, Maral R, Ninet L, Pinnert S, Preudhomme J, Werner GH (September 1964). "Rubidomycin: a new antibiotic with cytostatic properties". Cancer Chemotherapy Reports. 41: 35–6. PMID 14213139.

Arcamone F, Bernardi L, Giardino P, Patelli B, Di Marco A, Casazza AM, Pratesi G, Reggiani P (July 1976). "Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers". Cancer Treatment Reports. 60 (7): 829–34. PMID 1009518.

Ewer MS, Ewer SM (September 2015). "Cardiotoxicity of anticancer treatments". Nature Reviews. Cardiology. 12 (9): 547–58. doi:10.1038/nrcardio.2015.65. PMID 25962976. S2CID 9317756.

Chou H, Lin H, Liu JM (2015-07-13). "A tale of the two PEGylated liposomal doxorubicins". OncoTargets and Therapy. 8: 1719–20. doi:10.2147/OTT.S79089. PMC 4508070. PMID 26203262.

Barenholz Y (June 2012). "Doxil®--the first FDA-approved nano-drug: lessons learned". Journal of Controlled Release. 160 (2): 117–34. doi:10.1016/j.jconrel.2012.03.020. PMID 22484195.

Udhrain A, Skubitz KM, Northfelt DW (2007). "Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma". International Journal of Nanomedicine. 2 (3): 345–52. PMC 2676669. PMID 18019833.

Batist G (2007). "Cardiac safety of liposomal anthracyclines". Cardiovascular Toxicology. 7 (2): 72–4. CiteSeerX 10.1.1.529.9071. doi:10.1007/s12012-007-0014-4. PMID 17652807. S2CID 2815965.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Ewer MS, Ewer SM (September 2015). "Cardiotoxicity of anticancer treatments". Nature Reviews. Cardiology. 12 (9): 547–58. doi:10.1038/nrcardio.2015.65. PMID 25962976. S2CID 9317756.

Batist G (2007). "Cardiac safety of liposomal anthracyclines". Cardiovascular Toxicology. 7 (2): 72–4. CiteSeerX 10.1.1.529.9071. doi:10.1007/s12012-007-0014-4. PMID 17652807. S2CID 2815965.

worldcat.org

search.worldcat.org

Cancer management in man : chemotherapy, biological therapy, hyperthermia and supporting measures. Minev, Boris R. Dordrecht: Springer. 2011. ISBN 9789048197040. OCLC 704395391.{{cite book}}: CS1 maint: others (link)

DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology. DeVita, Vincent T., Jr., 1935-, Lawrence, Theodore S., Rosenberg, Steven A. (8th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2008. ISBN 9780781772075. OCLC 192027662.{{cite book}}: CS1 maint: others (link)

Anthracycline (English Wikipedia)

doi.org

fda.gov

accessdata.fda.gov

handle.net

hdl.handle.net

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

psu.edu

citeseerx.ist.psu.edu

semanticscholar.org

api.semanticscholar.org

worldcat.org

search.worldcat.org